Communicating complexity in gene therapy: the crucial role of medical affairs

An Expert View from Danie du Plessis, executive vice president, pharmaceutical operations at Kyowa Kirin International (TYO: 4151), and chair of the Medical Affairs Professional Society (MAPS) board.

Rapid scientific innovation and new technologies have driven major advances across the treatment pathway – from discovery and clinical development to launch and late lifecycle management.

As science has advanced, so too has the complexity of treatments, with new drugs and devices targeting specific patient populations across diverse geographic, racial, ethnic, age, comorbidity and treatment journey characteristics. At the same time, audiences desiring medical and scientific information have expanded, all of whom expect real-time, accurate information presented across a range of channels.